A comparative study of cefozopran for bacterial pneumonia

Abstract

A comparative study has been conducted to determine the clinical efficacy, safety and utility of a new injectable cephem antibiotic cefozopran (CZOP) versus a control drug, ceftazidime (CAZ), for bacterial pneumonia. CZOP and CAZ were administered, in principle, by intravenous drip infusion at a dose of 1.0g (potency), twice daily for 14days, and the following results were obtained: 1. The efficacy rates for the total number of cases evaluated were 90.5% (95/105) in the CZOP group and 96.0% (97/101) in the CAZ group. 2. Bacteriological eradication rates were 94.3% (50/53) in the CZOP group and 97.6% (41/42) in the CAZ group. 3. Adverse reaction rates were 6.2% (7/113) in the CZOP group and 3.4% (4/117) in the CAZ group. Abnormal laboratory finding rates were 27.0% (30/111) in the CZOP group and 31.6% (37/ 117) in the CAZ group. 4. Usefulness rates were 87.6% (92/105) in the CZOP group and 91.2% (93/102) in the CAZ group. These results indicate that CZOP is useful for the treatment of bacterial pneumonia. © 1993, Japanese Society of Chemotherapy. All rights reserved.